难治性重症肌无力患者的临床特征。
Clinical characteristics of refractory myasthenia gravis patients.
机构信息
Yale School of Medicine, Department of Neurology, Division of Neuromuscular Medicine, New Haven, Connecticut, USA.
出版信息
Yale J Biol Med. 2013 Jun 13;86(2):255-60. Print 2013 Jun.
BACKGROUND
A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group.
OBJECTIVE
The aim of our study is to describe the clinical features of refractory MG patients and compare them to those of non-refractory patients.
METHODS
A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011. Patients were classified as refractory or non-refractory based on predefined criteria, and clinical features were compared.
RESULTS
Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.
CONCLUSION
Refractory MG patients represent a small but distinct group for whom exploring newer therapeutic approaches and immunopathologic differences is warranted.
背景
一部分重症肌无力 (MG) 患者对标准治疗无反应。由于出现了可能对该人群更有效的新治疗策略，因此确定这部分人群的特征至关重要。
目的
我们的研究旨在描述难治性 MG 患者的临床特征，并将其与非难治性患者进行比较。
方法
对 2003 年至 2011 年期间转诊至三级神经肌肉诊所的 128 例 MG 患者进行了回顾性图表审查。根据预先确定的标准将患者分为难治性或非难治性，并比较了临床特征。
结果
128 例患者中有 19 例被归类为难治性（14.8%）。与非难治性患者相比，难治性患者发病年龄更小、女性、胸腺瘤和 MuSK 抗体阳性的可能性更大。
结论
难治性 MG 患者是一个人数较少但特征明显的群体，值得探索新的治疗方法和免疫病理差异。
Zotero 插件